购物车
- 全部删除
- 您的购物车当前为空
Glycophorin A Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 12.4 kDa and the accession number is P14220.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 2,660 | 5日内发货 | |
500 μg | ¥ 10,600 | 5日内发货 | |
1 mg | ¥ 17,800 | 5日内发货 |
生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | Glycophorin A Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 12.4 kDa and the accession number is P14220. |
种属 | Mouse |
表达系统 | HEK293 Cells |
标签 | C-His |
蛋白编号 | P14220 |
别名 | PAS-2,MNS,MN,HGpSta(C),HGpMiXI,HGpMiX,HGpMiV,HGpMiIII,GYPA,GPSAT,GpMiIII,GPErik,GPA,Glycophorin-A,Glycophorin A,CD235a |
蛋白构建 | Met1-Val108 |
蛋白纯度 | > 95% as determined by Tris-Bis PAGE |
分子量 | 12.4 kDa (predicted). Due to glycosylation, the protein migrates to 47-55 kDa based on Tris-Bis PAGE result. |
内毒素 | < 1 EU/μg by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
复溶方法 | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine.The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.